🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Small-intestine Neuroendocrine Tumors

A Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring to Assess Personal Cancer Risks NCT07469709n/a1 site📍 Candiolo Fondazione del Piemonte per l'Oncologia A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy NCT06362369Phase 1, Phase 25 sites📍 Aurora📍 Lake Mary📍 Lebanon 7 Hills Pharma, LLC · Tests: Alintegimod, Ipilimumab, Nivolumab START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer NCT05492682Phase 17 sites📍 Frankfurt📍 Heidelberg📍 Tübingen Valo Therapeutics Oy · Tests: PeptiCRAd-1, Cyclophosphamide, Pembrolizumab Microbiota and Carcinogenesis of Small-intestine Neuroendocrine Tumors NCT06624865n/a1 site📍 Lyon Hospices Civils de Lyon · Tests: Blood and stool sampling Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE) NCT04498767NA13 sites📍 Anderlecht📍 Ghent📍 Wilrijk European Organisation for Research and Treatment of Cancer … · Tests: Stereotactic body radiotherapy, Palliative RT Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program NCT06265285Phase 21 site📍 Jacksonville Mayo Clinic · Tests: Home Health Encounter, Nivolumab, Patient Monitoring, Questionnaire Administration A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements NCT03093116Phase 1, Phase 2165 sites📍 Duarte📍 Glendale📍 La Jolla Turning Point Therapeutics, Inc. · Tests: Oral repotrectinib (TPX-0005) A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors NCT07376707Phase 11 site📍 Shanghai Hefei TG ImmunoPharma Co., Ltd. · Tests: TGI-5 Integrated Cancer Repository for Cancer Research NCT02012699n/a42 sites📍 Greenwood Village📍 Manchester📍 Daytona Beach University of Nebraska Genomic Investigation of Unusual Responders NCT03740503n/a1 site📍 Toronto University Health Network, Toronto A Study of MGC026 in Participants With Advanced Solid Tumors NCT06242470Phase 112 sites📍 Los Angeles📍 Grand Rapids📍 Lake Success MacroGenics · Tests: MGC026 Dose Escalation, MGC026 Dose for Expansion, Pembrollizumab, vobramitamab tavatecan Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis NCT06047379Phase 1, Phase 28 sites📍 Beverly Hills📍 Glendale📍 Los Angeles Neonc Technologies, Inc. · Tests: NEO212 Oral Capsule, Ipilimumab, Pembrolizumab, Nivolumab, Regorafenib Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS NCT05379985Phase 1, Phase 221 sites📍 Orange📍 Santa Monica📍 Tampa Revolution Medicines, Inc. · Tests: RMC-6236 Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics NCT06418204n/a486 sites📍 Fairbanks📍 Kingman📍 Phoenix Wake Forest University Health Sciences · Tests: Non-interventional Study The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors NCT05037825n/a1 site📍 Elizabethtown VastBiome · Tests: Checkpoint Inhibitor, Immune Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer NCT05297734NA17 sites📍 Birmingham📍 Mobile📍 Duarte Stanford University · Tests: Receive technology-based supportive cancer care, Receive redesigned team-based supportive cancer care Patient Preference for Subcutaneous vs. Intravenous Immune Therapy NCT07223424Phase 21 site📍 Pittsburgh Diwakar Davar · Tests: nivolumab, pembrolizumab A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors NCT07749586Phase 1, Phase 24 sites📍 New York📍 Huntersville📍 San Antonio Arvinas Inc. · Tests: ARV-6723, Pembrolizumab, SOC Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05) NCT07327489n/a8 sites📍 Fort Smith📍 Frederick📍 Springfield Elephas · Tests: Biopsy SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry NCT03452774n/a68 sites📍 Birmingham📍 Mobile📍 Scottsdale Massive Bio, Inc. · Tests: Clinical Trial Matching Resection of the Primary Tumor vs. Systemic Treatment Alone for Patients With Small Intestinal Neuroendocrine Tumors and Unresectable Metastases: a Europe-wide Study NCT06787014n/a1 site📍 Bern Insel Gruppe AG, University Hospital Bern · Tests: Histopathological review A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors NCT05592626Phase 1, Phase 219 sites📍 Sacramento📍 Celebration📍 Miami Marengo Therapeutics, Inc. · Tests: STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere) Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors NCT07410494Phase 1, Phase 21 site📍 Beijing Essen Biotech · Tests: EB-SELECT Single-Target CAR-NK Cells, Dual-Target Antigen-Selected CAR-NK Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes NCT04907643NA1 site📍 Los Angeles Cedars-Sinai Medical Center · Tests: PICO G2 4k A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors NCT07636785Phase 1, Phase 21 site📍 Scottsdale VM Discovery, Inc. · Tests: VMD-102 A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors NCT06270706Phase 122 sites📍 New Haven📍 Atlanta📍 Grand Rapids Pliant Therapeutics, Inc. · Tests: PLN-101095, PLN-101095, PLN-101095, PLN-101095, PLN-101095 Use of 68Ga-DOTATOC PET/CT-enterography for Detection of the Primary Lesion in Neuroendocrine Tumors of the Small Bowel NCT06773624NA1 site📍 Milan European Institute of Oncology · Tests: PET/CT-enterography with 68Ga-DOTATOC DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. NCT05768178Phase 2, Phase 316 sites📍 Belfast📍 Birmingham📍 Bristol Cancer Research UK · Tests: Vemurafenib, Cobimetinib Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI NCT06333314Phase 222 sites📍 Angers📍 Avignon📍 Besançon UNICANCER · Tests: Dostarlimab, Chemotherapy Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies NCT04282044Phase 13 sites📍 Scottsdale📍 La Jolla📍 Stanford BioEclipse Therapeutics · Tests: CRX100 suspension for infusion, Fludarabine, Cyclophosphamide
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy